共 50 条
- [41] Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed TherapyBLOOD, 2023, 142Grajales-Cruz, Ariel F.Castaneda, OmarHansen, Doris K.Vazquez-Martinez, Mariola A.Blue, BrandonKhadka, SushmitaLiu, HienOchoa-Bayona, Jose L.Freeman, Ciara Louise L.Locke, Frederick L.Nishihori, TaigaShain, KennethBaz, RachidAlsina, Melissa
- [42] Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2022, 140 : 1360 - 1362Costa, Luciano J.Kumar, Shaji K.Atrash, ShebliLiedtke, MichaelaKaur, GurbakhashDerman, Benjamin A.Bergsagel, P. LeifMailankody, ShamMcCarthy, Philip L.Limones, JosianaChen, YanpingDas, SharmilaThorpe, JerillCacciatore, JonathanNavarro, GarnetKoegel, Ashley K.Burgess, Michael R.Hege, KristenRichard, Shambavi
- [43] Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter StudyBLOOD, 2023, 142Dima, DanaiSannareddy, AishwaryaAhmed, NausheenDavis, James A.Shaikh, HiraMahmoudjafari, ZahraDuco, MarissaKhouri, JackKaur, GurbakhashLochner, JonathanAnwar, FaizAfrough, AimazValent, JasonHashmi, HamzaAbdallah, Al-Ola
- [44] Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic ReviewBLOOD, 2019, 134Shah, ZunairahBatool, Syeda SabeekaFazeel, Hafiz MuhammadMalik, Mustafa NadeemSadiq, MaryamHassan, Syeda FatimaSyed, Tariq Iqtidar SadiqAbdullah, Syed MaazJaved, NismaAshraf, AqsaFarooqui, Arafat Ali AliYousaf, Muhammad AbdullahAhmad, Muhaddis EjazGhani, MariumAkbar, ArshiaAnwer, Faiz
- [45] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter TrialBLOOD, 2019, 134Costa, Luciano J.Wong, Sandy W.Bermudez, Aranchade la Rubia, JavierMateos, Maria-VictoriaOcio, Enrique M.Rodriguez-Otero, PaulaSan-Miguel, JesusLi, ShaoyiSarmiento, RafaelLardelli, PilarGaudy, AllisonBoss, IsaacKelly, Lisa M.Burgess, Michael R.Hege, KristenBensinger, William I.
- [46] Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S16Jagannath, SundarBerdeja, Jesus G.Jakubowiak, AndrzejAgha, MounzerCohen, AdamMadduri, DeepuHari, ParameswaranYeh, Tzu-MinOlyslager, YunsiBanerjee, ArnobJackson, Carolyn C.Allred, AliciaZudaire, EnriqueDeraedt, WilliamWu, XiaolingPacaud, LidaAkram, MuhammadLin, YiMartin, ThomasUsmani, Saad Z.
- [47] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69Polepally, A.Badillo, J.Rinas, M.Ahsan, A.Bueno, O.Talati, C.Menon, R.Engelhardt, B.
- [48] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Krishnan, Amrita Y.Garfall, Alfred L.Mateos, Maria-Victoriavan de Donk, Niels W. C. J.Nahi, HarethSan-Miguel, Jesus F.Oriol, AlbertRosinol, LauraChari, AjaiBhutani, ManishaKarlin, LionelBenboubker, LotfiPei, LixiaVerona, RalucaGirgis, SuzetteStephenson, TaraGoldberg, Jenna D.Banerjee, ArnobUsmani, Saad Zafar
- [49] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Ahsan, AarifMantis, ChristineLuo, XizhiZhang, Catherine C.Valdes, Cesar RodriguezVoorhees, Peter M.D'Souza, AnitaChung, AlfredTuchman, SaschaSafah, HanaMckay, John T.Weisel, Katja C.Teipel, RaphaelKorde, NehaVij, RaviKumar, ShajiBueno, Orlando FelixPothacamury, Rajvineeth KumarTalati, ChetasiRoss, Jeremy A.
- [50] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 StudyBLOOD, 2022, 140Bahlis, Nizar JacquesTomasson, Michael H.Mohty, MohamadNiesvizky, RubenNooka, Ajay K.Manier, SalomonMaisel, ChristopherJethava, YogeshMartinez-Lopez, JoaquinPrince, H. MilesArnulf, BertrandRodriguez Otero, PaulaKoehne, GuentherTouzeau, CyrilleRaje, NoopurIida, ShinsukeRaab, Marc-SteffenLeip, EricSullivan, SharonConte, UmbertoViqueira, AndreaLesokhin, Alexander M.